News
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology
Founded by Medicxi with Georgia Tech and UMass scientists,…
DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish…
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
MacroGenics adds up to four ADC programs
MacroGenics may…
Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met
First-in-class SK channel inhibition proof of mechanism achieved
First…
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
Financing co-led by Sunstone Life Science Ventures and…
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
BioInnovation Institute welcomes innovative mycoprotein meat project into Bio Studio program
BioInnovation Institute (BII), an international non-profit foundation…
Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent
Key highlights
· Patent granted for use of certain…
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Transformational results in Phase 3 ENHANCE program for COPD
NDA…
Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for…
Ten new companies enter BioInnovation Institute’s Venture Lab program
BioInnovation Institute (BII), an international non-profit foundation…
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
Phase 1 clinical trial (CHIHUAHUA) demonstrates that single…
Destiny Pharma plc – Fundraising to raise up to £8 million
Fundraising to raise up to £8 million
Destiny Pharma plc (AIM:…
Destiny Pharm plc – Agreement with Sebela Pharmaceuticals for NTCD-M3
Exclusive collaboration and co-development agreement for NTCD-M3…
Novo Holdings invests in water technology company Aquafortus
Aquafortus, a water technology company that purifies high salinity…
Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemics
Fourteen research projects will focus on antiviral research…
Prof. Molly Stevens receives the Novo Nordisk Prize – Understanding how materials and biology interact has revolutionised healthcare technologies
Science of small things does not sound like something that…
Novo Holdings participates in Hemab Therapeutics $135M Series B Financing
Hemab Therapeutics is a clinical-stage biotechnology company…
Methinks receives CE Marked Certification for AI-based stroke triage software
Methinks Stroke Suite is a disruptive technology that has the…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
